[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Ryan CW, Montag AG, Hosenpud JR, Samuels B, Hayden JB, Hung AY, Mansoor A, Peabody TD, Mundt AJ, Undevia S: Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer; 2008 Jun;112(11):2432-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
  • BACKGROUND: The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas.
  • METHODS: Twenty-five patients with intermediate-grade or high-grade, localized soft tissue sarcomas of the extremity or body wall measuring >5 cm were treated with epirubicin at a dose of 30 mg/m(2)/day on Days 1 to 4 and ifosfamide at a dose of 2.5 g/m(2)/day on Days 1 to 4 every 21 days for 3 preoperative and 3 postoperative cycles.
  • A total of 28 grays of radiation was administered over 8 fractions during Cycle 2 of preoperative therapy (epirubicin was omitted).
  • RESULTS: Sixteen patients (64%) completed all chemotherapy cycles and the average delivered dose intensity relative to intended therapy was 69%.
  • Postoperative wound complications requiring a surgical procedure occurred in 20% of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Epirubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Jun;112(11):2338-40 [18338757.001]
  • (PMID = 18348295.001).
  • [ISSN] 1097-0142
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Zhang Q, Wojno TH, Yaffe BM, Grossniklaus HE: Myxofibrosarcoma of the orbit: a clinicopathologic case report. Ophthal Plast Reconstr Surg; 2010 Mar-Apr;26(2):129-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 27-year-old woman developed a rapidly progressive left orbital tumor that extended in the cranial fossa.
  • Complete excision with postoperative adjuvant radiation therapy and chemotherapy was performed, and the patient had no evidence of tumor recurrence within 6 months' follow-up.
  • Myxofibrosarcoma is a fibroblast-derived soft tissue neoplasm with up to a 60% local recurrence rate, and metastasis may be associated with intermediate to high-grade tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Oct;35(4):291-312 [10564384.001]
  • [Cites] Hum Pathol. 2004 May;35(5):612-21 [15138937.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1977 Mar;85A(2):127-40 [15396.001]
  • [Cites] Cancer. 1977 Apr;39(4):1672-85 [192434.001]
  • [Cites] Skeletal Radiol. 2008 Dec;37(12):1085-90 [18629459.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):391-405 [8604805.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):117-9 [15735866.001]
  • [Cites] Ophthalmology. 2008 Jul;115(7):1237-1240.e2 [18096231.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand Suppl. 1983;282:1-40 [6444190.001]
  • (PMID = 20305519.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY006360; None / None / / P30 EY006360-25; United States / NEI NIH HHS / EY / P30 EY006360-25
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS239382; NLM/ PMC2983108
  •  go-up   go-down


3. Punt SE, Eary JF, O'Sullivan J, Conrad EU: Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics. Nucl Med Commun; 2009 Jul;30(7):546-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics.
  • OBJECTIVE: Leiomyosarcoma, a malignant neoplasm of smooth muscle, accounts for 7% of the sarcomas.
  • These tumors, which are derived from mesenchymal tissues, are difficult to diagnose, and treatment options remain controversial.
  • The relatively rare incidence of this soft tissue sarcoma subtype has limited the number of patients available for studies and research.
  • This study examines whether the imaging characteristics of positron emission tomography (PET) with radiolabeled fluorodeoxyglucose (FDG) provide a reliable, noninvasive means to predict tumor behavior in patients with leiomyosarcomas.
  • METHODS: [18F]-FDG-PET was performed on the tumors of participating patients before the neoadjuvant chemotherapy or resection, and a maximum tumor standard uptake value (SUVmax) was calculated.
  • The results of this study suggest that a large (by greatest dimension) intermediate grade tumor is expected to have the same predicted outcome as a high-grade tumor and should be treated in the same manner, as they share the same prognosis by definition of tumor grade.
  • Improvements made in the clinical treatment of leiomyosarcomas by use of FDG-PET imaging data may lead to an increase in patient survival.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004;86-A Suppl 2:98-104 [15691114.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8828-34 [16314643.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1215-20 [9607579.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):500-5 [10749609.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Skeletal Radiol. 2001 Oct;30(10):543-59 [11685477.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54 [12192559.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):930-42 [12791822.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):701-4 [14766270.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):189-95 [15129700.001]
  • [Cites] Ir J Med Sci. 2011 Dec;180(4):889-91 [19184604.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jun;467(6):1605-11 [19048352.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(17-18):557-60 [17943409.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1826-9; discussion 1829-30 [17462407.001]
  • [Cites] Kyobu Geka. 2006 Dec;59(13):1191-6 [17163213.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1290-5 [16832631.001]
  • (PMID = 19440162.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA065537-13; United States / NCI NIH HHS / CA / R01 CA065537; United States / NCI NIH HHS / CA / R01 CA 65537; United States / NCI NIH HHS / CA / R01 CA065537-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS121746; NLM/ PMC2752415
  •  go-up   go-down


Advertisement
4. Li L, Shi YH, Guo ZJ, Qiu T, Guo L, Yang HY, Zhang X, Zhao XM, Su Q: Clinicopathological features and prognosis assessment of extranodal follicular dendritic cell sarcoma. World J Gastroenterol; 2010 May 28;16(20):2504-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgical resection was performed in 100 patients, followed by radiation and/or chemotherapy in 35 of them.
  • The lesions were defined as low-, intermediate- and high-risk tumors, and their recurrence rates were 16%, 46% and 73%, and their mortality rates 0%, 4% and 45%, respectively.
  • CONCLUSION: Extranodal FDC tumors behave like soft tissue sarcomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Review Literature as Topic. Sarcoma / pathology. Treatment Outcome. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2008 May;39(5):776-80 [18291441.001]
  • [Cites] Pathol Res Pract. 2009;205(2):149-53 [18774654.001]
  • [Cites] Jpn J Radiol. 2009 Jan;27(1):4-19 [19373526.001]
  • [Cites] Arch Pathol Lab Med. 2009 Apr;133(4):643-7 [19391666.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):236-46 [19546611.001]
  • [Cites] Ann Diagn Pathol. 2009 Aug;13(4):257-62 [19608084.001]
  • [Cites] J Cardiothorac Surg. 2009;4:31 [19589162.001]
  • [Cites] Chin Med J (Engl). 2009 Jul 5;122(13):1595-7 [19719956.001]
  • [Cites] Histopathology. 2006 Oct;49(4):431-3 [16978210.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2290-2 [10561286.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):365-80 [10767646.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):882-8 [10843293.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):664-72 [10931467.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1693-6 [11079028.001]
  • [Cites] Histopathology. 2001 Jan;38(1):25-9 [11135043.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):354-60 [11301353.001]
  • [Cites] Head Neck. 1999 May;21(3):273-5 [10208672.001]
  • [Cites] Am J Dermatopathol. 2005 Aug;27(4):327-32 [16121055.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):721-31 [11395549.001]
  • [Cites] Histopathology. 2001 Jun;38(6):510-8 [11422494.001]
  • [Cites] Surgery. 2001 Jul;130(1):109-11 [11436023.001]
  • [Cites] Hum Pathol. 2001 Jul;32(7):745-9 [11486174.001]
  • [Cites] Hum Pathol. 2001 Dec;32(12):1403-7 [11774177.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):50-8 [11796841.001]
  • [Cites] Am J Otolaryngol. 2002 Mar-Apr;23(2):93-8 [11893977.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Haematologica. 2003 Feb;88(2):ECR04 [12604428.001]
  • [Cites] Oral Oncol. 2003 Jun;39(4):415-9 [12676264.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):124-31 [14720144.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):259-63 [14991546.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):569-77 [15105643.001]
  • [Cites] Biotechniques. 2004 Jun;36(6):932-3 [15211740.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):988-98 [15252304.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Apr-Jun;67(2):223-7 [15285580.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):562-72 [2420185.001]
  • [Cites] Mol Cell Biol. 1986 May;6(5):1379-85 [2946935.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] EMBO J. 1992 Oct;11(10):3513-20 [1396554.001]
  • [Cites] Oncogene. 1993 Feb;8(2):307-18 [8426740.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):517-25 [8172326.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):90-7 [7817952.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1363-70 [7478558.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):747-53 [8651355.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):944-55 [8712294.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):313-24 [8772785.001]
  • [Cites] Histopathology. 1996 Jan;28(1):89-92 [8838129.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):294-313 [9010103.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1295-306 [9351567.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):703-6 [9361105.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):293-8 [9532010.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2230-8 [9649138.001]
  • [Cites] Clin Chem. 1998 Jul;44(7):1397-403 [9665415.001]
  • [Cites] Histopathology. 1998 Nov;33(5):465-70 [9839172.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Feb;87(2):209-14 [10052377.001]
  • [Cites] Head Neck. 1999 Mar;21(2):164-7 [10091986.001]
  • [Cites] Ann Diagn Pathol. 1999 Apr;3(2):92-8 [10196389.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2008 Jan;37(1):40-4 [18509984.001]
  • [Cites] Arch Pathol Lab Med. 2008 Oct;132(10):1683-7 [18834231.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2008 Jun;37(6):395-9 [19031719.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):725-7 [15926163.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1480-3 [16253031.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9425-6 [16361643.001]
  • [Cites] Am J Otolaryngol. 2006 May-Jun;27(3):207-10 [16647987.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):249-53 [16533803.001]
  • [Cites] Pathol Res Pract. 2006;202(7):541-8 [16564140.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):466-70 [16872443.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):148-58 [16758173.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):662-9 [11979097.001]
  • [Cites] Arch Pathol Lab Med. 2006 Nov;130(11):1718-21 [17076538.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Dec;263(12):1155-7 [16896752.001]
  • [Cites] Ann Diagn Pathol. 2006 Dec;10(6):357-62 [17126255.001]
  • [Cites] Clin Transl Oncol. 2006 Nov;8(11):837-8 [17134976.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):668-72 [17367608.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):W554-6 [17515347.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):725-8 [17373675.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):346-52 [17721283.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2007 Jun;36(6):430-1 [17822636.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):776-82 [17951199.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jan;65(1):1-7 [17658269.001]
  • [Cites] Diagn Cytopathol. 2008 Jan;36(1):42-6 [18064686.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2007 Oct;36(10):660-5 [18194598.001]
  • (PMID = 20503450.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2877180
  •  go-up   go-down


5. Sanmartín O, Llombart B, López-Guerrero JA, Serra C, Requena C, Guillén C: [Dermatofibrosarcoma protuberans]. Actas Dermosifiliogr; 2007 Mar;98(2):77-87
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatofibrosarcoma protuberans (DFSP) is a soft tissue neoplasm of intermediate malignancy that is initially localized to the skin from where it can invade deep structures (fat, fascia, muscle and bone).
  • It is the most frequent fibrohistiocytic tumor, comprising approximately 1.8 % of all soft tissue sarcomas and 0.1 % of all cancers.
  • Treatment of localized disease consists in complete surgical excision of the lesion by conventional surgery with wide margins (>3 cm) or by micrographic Mohs surgery.
  • The prognosis for metastatic cases is very poor with a survival of less than 2 years following detection of metastatic disease.
  • Patients with locally advanced DFSP are not candidates for an initial radical surgical therapy therefore neoadyuvant treatment is required prior to surgery in order to reduce tumor burden.
  • In this regard, chemotherapy and radiotherapy have not been highly efficacious so it is necessary to consider new alternatives.
  • The demonstration of the oncogenic power of the translocation COL1A1-PDGFB in DFSP has allowed the successful introduction of drug therapy with antagonists of the PDGFB receptor for metastatic or locally advanced cases.
  • [MeSH-minor] Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 17 / ultrastructure. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 22 / ultrastructure. Combined Modality Therapy. Dermatofibrosarcoma / chemistry. Dermatofibrosarcoma / classification. Dermatofibrosarcoma / drug therapy. Dermatofibrosarcoma / genetics. Dermatofibrosarcoma / pathology. Dermatofibrosarcoma / surgery. Drug Design. Humans. Imatinib Mesylate. Mohs Surgery. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Piperazines / therapeutic use. Prognosis. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Ring Chromosomes. Sarcoma / chemistry. Sarcoma / drug therapy. Sarcoma / genetics. Sarcoma / pathology. Sarcoma / surgery. Translocation, Genetic

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397592.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / COLIA1-PDGFB fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Number-of-references] 68
  •  go-up   go-down


6. Ehrhart N: Soft-tissue sarcomas in dogs: a review. J Am Anim Hosp Assoc; 2005 Jul-Aug;41(4):241-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas in dogs: a review.
  • Soft-tissue sarcomas are a heterogeneous group of tumors with similar biological behaviors.
  • Wide surgical excision remains the cornerstone of treatment for these tumors.
  • Radiation therapy or re-excision with wider margins is indicated if excision is microscopically incomplete.
  • Chemotherapy is often recommended as an adjunctive treatment for high-grade soft-tissue sarcomas because of their higher metastasis rates when compared to low-or intermediate-grade soft-tissue sarcomas.
  • Knowledge of extent of disease and histological grade is helpful in guiding treatment choices.
  • [MeSH-major] Dog Diseases / drug therapy. Dog Diseases / surgery. Sarcoma / veterinary. Soft Tissue Neoplasms / veterinary
  • [MeSH-minor] Animals. Chemotherapy, Adjuvant / veterinary. Dogs. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / veterinary. Neoplasm Staging / veterinary. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995161.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


7. Evans SM, Fraker D, Hahn SM, Gleason K, Jenkins WT, Jenkins K, Hwang WT, Zhang P, Mick R, Koch CJ: EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys; 2006 Mar 1;64(3):922-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EF5 binding and clinical outcome in human soft tissue sarcomas.
  • PURPOSE: To study the 2-nitroimidazole agent EF5 as a surrogate for measuring hypoxia in a series of patients with soft tissue sarcomas, and to determine whether hypoxia measured with this technique was associated with patient outcome.
  • METHODS AND MATERIALS: Patients with soft tissue sarcomas of the head and neck, extremity, trunk, or retroperitoneum for whom surgical excision was the initial treatment of choice, were given 21 mg/kg EF5 24-48 hours before surgery.
  • There were seven low-grade, one intermediate-grade, and eight high-grade tumors.
  • Such data should be useful to identify high-risk patients for clinical trials to determine whether early chemotherapy will influence the occurrence of metastasis.
  • [MeSH-major] Cell Hypoxia / physiology. Etanidazole / analogs & derivatives. Hydrocarbons, Fluorinated / metabolism. Indicators and Reagents / metabolism. Neoplasm Recurrence, Local / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458778.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00040; United States / NCI NIH HHS / CA / R01 CA 75285
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / Hydrocarbons, Fluorinated; 0 / Indicators and Reagents; 30DKA3Q1HL / Etanidazole
  •  go-up   go-down


8. Ruymann FB, Grovas AC: Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest; 2000;18(3):223-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
  • Advances in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas continue in the Intergroup Rhabdomyosarcoma Study Group (IRSG) and European cooperative groups.
  • The use of molecular biology techniques in soft tissue sarcomas are redefining the classic pathology of these small blue cell tumors.
  • These advances confound the interpretation of consecutively run chemotherapy trials using historical comparisons.
  • The IRSG has reported improvement in the prognosis of both nonmetastatic and metastatic embryonal rhabdomyosarcoma as attributable to three, three-drug regimens that use cyclophosphamide at 2.2 g/m2 in either maintenance or induction and maintenance therapy.
  • The doublet of ifosfamide and etoposide in combination with vincristine, actinomycin D, and cyclophosphamide at 2.2 g/m2 achieved a remarkable 3-year survival of 58% in patients with metastatic rhabdomyosarcoma and undifferentiated soft tissue sarcoma.
  • Topotecan has completed testing with cyclophosphamide in a phase II window study in newly diagnosed patients with metastatic disease and has been incorporated into a randomized trial in intermediate risk patients in IRSG-V.
  • Molecular studies in IRSG-V will be applied in the detection of occult bone marrow metastases and the evaluation of resection margins at initial and second-look surgery.
  • As molecular discoveries advance the diagnosis and detection of rhabdomyosarcoma, it is hoped that the futuristic molecular based treatment strategies in development and early testing will further improve survival in high-risk patients with metastatic soft tissue sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma / diagnosis. Sarcoma / therapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Medical Oncology / trends. Neoplasm Metastasis. Neoplasm Staging. Pediatrics / trends. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10754991.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / U10 CA03750-39; United States / NCI NIH HHS / CA / U10 CA24507-17
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 121
  •  go-up   go-down


9. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer; 2008 Nov;44(16):2433-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
  • RATIONALE: Angiosarcomas of soft tissue represent a heterogenous group of rare sarcomas with specific clinical behaviour and risk factors.
  • METHOD: Clinical data from patients with angiosarcomas of soft tissue treated with single agent paclitaxel were collected from the centres of the soft tissue and bone sarcoma group of EORTC, using a standardised data collection form.
  • All patients had intermediate (n=13) or high grade (n=19) primary tumours.
  • Thirteen (40%) patients had been pretreated with doxorubicin-based first-line-chemotherapy and three of them (9%) had also received second-line chemotherapy with ifosfamide.
  • Eleven (34%) patients had been irradiated before as treatment for angiosarcoma.
  • In 8 (25%) patients, the angiosarcoma occurred at sites of prior radiation therapy for other malignancies.
  • The median time to progression was 7.6 months (range, 1-42) for the whole group.
  • CONCLUSION: Paclitaxel was found to be an active agent in angiosarcoma of soft tissue in this retrospective analysis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangiosarcoma / drug therapy. Paclitaxel / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies. Scalp. Skin Neoplasms / drug therapy. Young Adult


10. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS.
  • PATIENTS AND METHODS Patients with intermediate- or high-grade advanced STS who were ineligible for chemotherapy or who had received no more than two prior cytotoxic agents for advanced disease, who had documented progression, who had adequate performance status, and who had good organ function were eligible.
  • Four different strata were studied: adipocytic STS, leiomyosarcomas, synovial sarcomas, and other STS types.
  • PFR(12 weeks) was 18 (44%) of 41 patients in the leiomyosarcoma cohort, 18 (49%) of 37 in the synovial sarcomas, and 16 (39%) of 41 in the other STS types.
  • Compared with historical controls who were treated with second-line chemotherapy, progression-free and overall survivals were prolonged in the three cohorts in which the primary end point was reached.
  • The most frequent drug-related toxicities were hypertension, fatigue, hypopigmentation, and nausea.
  • CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  •  go-up   go-down


11. Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR: Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol; 2001 Jul 01;19(13):3203-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
  • PURPOSE: To determine whether treatment-induced pathologic necrosis correlates with local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
  • PATIENTS AND METHODS: Four hundred ninety-six patients with intermediate- to high-grade extremity soft tissue sarcomas received protocol neoadjuvant therapy.
  • All patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tumor necrosis in the resected specimens.
  • Patients with less than 95% pathologic necrosis were 2.51 times more likely to develop a local recurrence and 1.86 times more likely to die of their disease as compared with patients with > or = 95% pathologic necrosis.
  • CONCLUSION: Treatment-induced pathologic necrosis is an independent predictor of both local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoadjuvant Therapy / adverse effects. Neoplasm Recurrence, Local / epidemiology. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432887.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; IAP protocol
  •  go-up   go-down


12. Orbach D, Glorion C, Mary P, Freneaux P, Brisse H, Helfre S, Schleiermacher G, Pacquement H: [Malignant tumours of the locomotor apparatus in children: an "intermediate" prognosis]. Rev Prat; 2007 May 31;57(10):1080-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumours of the locomotor apparatus in children: an "intermediate" prognosis].
  • Malignant tumours of the locomotor apparatus in children mainly comprise bone tumours such as osteosarcoma or Ewing's sarcoma and soft tissue sarcomas such as rhabdomyosarcoma.
  • The diagnosis must be considered in any case of progressively worsening limb pain at a fixed site, possibly associated with a soft tissue mass.
  • Treatment must be adapted to the known prognostic factors, mainly tumour operability, initial size, histological type, response to neoadjuvant chemotherapy and initial staging.
  • Treatment must comprise neoadjuvant chemotherapy followed by local treatment combining radical surgery with reconstruction if necessary and sometimes external beam radiotherapy.
  • This treatment must be completed by postoperative adjuvant chemotherapy resulting in an average total duration of treatment between 6 and 12 months.
  • Long-term follow-up is designed to ensure absence of disease recurrence, attentive orthopaedic follow-up and absence of late sequelae related to anticancer therapy.
  • [MeSH-major] Bone Neoplasms / therapy. Lower Extremity / pathology. Muscle Neoplasms / therapy. Soft Tissue Neoplasms / therapy. Upper Extremity / pathology
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Child. Diagnostic Imaging. Follow-Up Studies. Humans. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Osteosarcoma / therapy. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / therapy. Sarcoma / therapy. Sarcoma, Ewing / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17844801.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Tsavaris N, Kosmas C, Zorzos H, Lazaris A, Vadiaka M, Dimitrakopoulos A, Siakantaris MP, Rokana S, Papalambros E, Pangalis GA, Davaris P: Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. Oncol Rep; 2004 Apr;11(4):899-903
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
  • We examined the outcome of patients who developed breast cancer after curative chemotherapy (CHOP) for aggressive non-Hodgkin's lymphoma (NHL) in comparison to the outcome of a retrospectively selected matched-pair group of patients with de novo breast cancer, and evaluated the role of drug resistance-related protein (MDR, MRP, LRP) expression in breast cancer tissue.
  • The median age was 62 (49-70) years, each had high/intermediate grade B-cell NHL treated with 6 courses of CHOP, and were in complete remission.
  • These patients were compared to a matched-pair group of de novo BC patients selected from our database over the same time period.
  • Breast cancer tissue was stained by immunohistochemistry for drug resistance proteins LRP, MRP, and MDR.
  • Breast cancer developed after a median of 26 (9-49) months of NHL diagnosis; breast tumor grades 1-2 were seen in 12, and grade 3 in 10 patients; 15 were negative and 7 weakly positive for estrogen and progesterone receptors.
  • Twelve patients were stage IIIA/B, and 10 stage IV and were treated with conventional chemotherapy regimens.
  • All progressed early in liver (n=13), brain (n=9), lung (n=6), bone (n=8), lymph nodes (n=7) and soft tissue (n=5), and received second-line chemotherapy with mitomycin-C + vinblastine or taxanes.
  • Time from NHL to breast cancer development was 19 (14-27) months in patients with positive drug resistance proteins (group A), and 37 (26-56) months in patients with 1 or 2 positive resistance proteins (group B) (p<0.001).
  • Patients in the control matched-pair group had more prolonged OS when compared to group A patients who developed BC in <24 months from NHL to BC (p=0.017).
  • We conclude that breast cancer developing shortly after a complete response in NHL, is an aggressive disease variant with minimal potential for response to conventional chemotherapy.
  • Analysis of drug resistance mechanisms concerning MDR, MRP and LRP indicates that most of these patients have BC that overexpress these proteins leading to the suggestion that these mechanisms might be a part of the aggressive disease phenotype and partially explain the poor outcome.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunochemistry. Membrane Transport Proteins / analysis. Membrane Transport Proteins / metabolism. Middle Aged. Multidrug Resistance-Associated Proteins / analysis. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoproteins / analysis. P-Glycoproteins / metabolism. Prednisone / therapeutic use. Prognosis. Protein Tyrosine Phosphatases / analysis. Protein Tyrosine Phosphatases / metabolism. Receptor-Like Protein Tyrosine Phosphatases, Class 4. Receptors, Cell Surface / analysis. Receptors, Cell Surface / metabolism. Retrospective Studies. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15010892.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoproteins; 0 / Receptors, Cell Surface; 0 / multidrug resistance-associated protein 2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / PTPRA protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 4; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P: Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol; 2001 Jan;12(1):81-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy.
  • BACKGROUND: Analysis of prognostic factors in patients with metastatic breast cancer treated with epirubicin-based chemotherapy.
  • PATIENTS AND METHODS: Data from 469 patients treated with epirubicin-based chemotherapy for metastatic breast cancer were used.
  • RESULTS: The prognostic factors identified were: liver, pleural, soft tissue, lung and bone metastases, performance status > 2, advancing age, abnormal elevation of serum lactate dehydrogenase and negative/unknown oestrogen receptor status.
  • Four risk groups were established: good, intermediate I, intermediate II and poor.
  • The median and five-year survivals in percentage were: good: 34 months (26%); intermediate I: 19 months (6%), intermediate II: 12 months (0%); poor: 7 months (1%).

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11249054.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


15. Chauvet B, de Rauglaudre G, Mineur L, Alfonsi M, Reboul F: [Dose-response relationship in radiotherapy: an evidence?]. Cancer Radiother; 2003 Nov;7 Suppl 1:8s-14s

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite many clinical datas, difficulties remain to demonstrate a relation between dose and local control: relative role of treatment associated with radiation therapy (surgery, chemotherapy, hormonal therapy), tumor heterogeneity, few prospective randomized studies, uncertainty of local control assessment.
  • Three different situations are discussed: tumors with high local control probabilities for which dose effect is demonstrated by randomized studies (breast cancer) or sound retrospective datas (soft tissues sarcomas), tumors with intermediate local control probabilities for which dose effect seems to be important according to retrospective studies and ongoing or published phase III trials (prostate cancer), tumors with low local control probabilities for which dose effect appears to be modest beyond standard doses, and inferior to the benefit of concurrent chemotherapy (lung and oesophageal cancer).
  • For head and neck tumors, the dose-response relationship has been explored through hyperfractionation and accelerated radiation therapy and a dose effect has been demonstrated but must be compared to the benefit of concurrent chemotherapy.
  • Last but not least, the development of conformal radiotherapy allow the exploration of the dose response relationship for tumors such as hepatocellular carcinomas traditionally excluded from the field of conventional radiation therapy.
  • In conclusion, the dose-response relationship remains a sound basis of radiation therapy for many tumors and is a parameter to take into account for further randomized studies.
  • [MeSH-minor] Adult. Breast Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose Fractionation. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / mortality. Esophageal Neoplasms / radiotherapy. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Prognosis. Prostatic Neoplasms / radiotherapy. Radiation Tolerance. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Retrospective Studies. Risk Factors. Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15124539.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 41
  •  go-up   go-down


16. McGrory JE, Rock MG, Nascimento AG, Oliveira AM: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res; 2001 Jan;(382):185-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of the primary site included wide excision or amputation in 13 patients and marginal or intralesional resections with radiation in three patients.
  • Local recurrence developed in four, and metastases developed in six of 13 patients presenting with localized disease.
  • Of six patients who received chemotherapy for systemic disease, four had disease progression and died, and two had a response to chemotherapy (one partial, one complete).
  • The current series suggests that extraskeletal myxoid chondrosarcoma is an intermediate-grade neoplasm with a tendency toward recurrence and metastasis.
  • More effective therapy for systemic disease is needed.
  • [MeSH-major] Chondrosarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leg / surgery. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11153986.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, DeLaney TF, Yoon SS: Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol; 2007 Jun;14(6):1953-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of 82 patients with angiosarcoma.
  • BACKGROUND: Angiosarcomas are an uncommon type of malignancy that are generally thought to behave usually in a locally aggressive fashion; they often metastasize to distant sites.
  • METHODS: Patients with a diagnosis of angiosarcoma treated at our institution between 1980 and 2006 were analyzed for patient demographics, tumor characteristics, multimodality treatment, and outcomes.
  • Median size of tumors was 3.8 cm, and 76% of tumors were intermediate or high grade.
  • Tumors were located throughout the body: 32 cutaneous, 22 deep soft tissues or organs, 10 radiation or lymphedema field, 8 bone, and 7 nonirradiated breast.
  • Of 46 patients with primary disease, all patients underwent surgical resection, 67% received radiotherapy, and 27% received chemotherapy.
  • Five-year disease-specific survival was 60%, and negative prognostic factors included intermediate or high grade, and tumors arising in a radiated or lymphedema field.
  • Of 36 patients with advanced disease, 36% underwent a palliative operation, 78% received radiation, and 58% received chemotherapy.
  • The role of adjuvant chemotherapy is unclear.
  • Patients with advanced disease have a poor prognosis, but there can be dramatic responses to chemotherapy in a minority of patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / surgery. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356953.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5K12CA87723-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Ruiz-Tovar J, Fernández Guarino M, Reguero Callejas ME, Aguilera Velardo A, Arano Bermejo J, Cabañas Navarro L: Dermatofibrosarcoma protuberans: review of 20-years experience. Clin Transl Oncol; 2006 Aug;8(8):606-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue neoplasm with low-intermediate grade of malignancy.
  • Surgical excision with adequate margins is the main treatment.
  • Chemotherapy could be indicated in metastasic cases.
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jun 15;88(12):2711-20 [10870053.001]
  • [Cites] Anticancer Drugs. 2005 Apr;16(4):461-6 [15746584.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2503-8 [15503305.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):392-7 [10419710.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):241-8 [1607035.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3586-91 [12202658.001]
  • [Cites] J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):355-74; quiz 375-6 [8784271.001]
  • [Cites] Am J Dermatopathol. 1993 Oct;15(5):429-34 [7694515.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):823-7 [9531366.001]
  • (PMID = 16952850.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, Hara J, Mitsui T, Kaneko M, Hatae Y, Hayashi Y, Mabuchi O, Adachi N, Morikawa Y, Nishimura S, Kumagai M, Takamatsu H, Sawada T, Sugimoto T: A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol; 2007 Apr;12(2):137-45
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ten-year survival rates were 86.3% for patients in low-risk subgroup A, 80.7% for low-risk subgroup B, 62.7% for intermediate-risk subgroup A, 61.7% for intermediate-risk subgroup B, and 38.1% for the high-risk group.
  • Among the patients in the high-risk group, the 5-year survival of patients who received high-dose chemotherapy (HDC; 58.2%) was significantly better than that of patients who did not receive HDC (18.4%).
  • CONCLUSION: Patients in the lower-risk groups with embryonal-type tumors had poorer outcomes in this retrospective study.
  • (1) a standard therapy, (2) a rapid central pathology review including a chimera gene analysis for the lower-risk group, and (3) evaluation of the efficacy of the high-dose regimen for the high-risk group in Japan.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Child. Child, Preschool. Female. Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Humans. Infant. Japan / epidemiology. Male. Neoplasm Staging. Orbital Neoplasms / drug therapy. Orbital Neoplasms / mortality. Retrospective Studies. Risk Factors. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / mortality. Surveys and Questionnaires. Survival Rate. Time Factors. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Clin Biol Res. 1994;385:371-5 [7972233.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22(1):7-12 [9678789.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Jpn J Surg. 1990 Sep;20(5):503-9 [2243442.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):46-54 [3543238.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Apr-May;20(3):201-10 [12637216.001]
  • (PMID = 17443282.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Pritsch T, Bickels J, Winberg T, Malawer MM: Popliteal sarcomas: presentation, prognosis, and limb salvage. Clin Orthop Relat Res; 2007 Feb;455:225-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas of the popliteal fossa are rare diseases.
  • Their prognosis is inferior to intracompartmental extremity soft tissue sarcomas.
  • Sixteen, five, and eight patients were diagnosed with high-, intermediate-, and low-grade tumors, respectively.
  • High-grade tumors were smaller than low- and intermediate-grade tumors.
  • Seventeen patients were treated with radiotherapy and 10 patients received chemotherapy.
  • Soft tissue sarcomas of the popliteal fossa have an atypical presentation.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Limb Salvage. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957647.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


22. Martin DR, Danrad R, Herrmann K, Semelka RC, Hussain SM: Magnetic resonance imaging of the gastrointestinal tract. Top Magn Reson Imaging; 2005 Feb;16(1):77-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Removal of fat signal for detection of enhancing normal and abnormal structures is critical.
  • Generalized protocol for comprehensive evaluation of the entire abdomen and pelvis can be used for the following bowel indications: type and severity of inflammatory bowel disease (IBD); identifying enteric abscesses and fistulae; preoperative staging of malignant neoplasms, including rectal carcinoma; differentiating postoperative and radiation therapy changes from recurrent carcinoma; follow-up evaluation of metastases response to localized ablative or systemic chemotherapy.
  • Strengths include: performed without fat suppression results in the very dark bowel wall being sandwiched between intermediate high signal fat adjacent to bowel serosa, and very high lumen signal from water-distending agent; 2D True-FISP provides motion insensitivity that is lost if 3D is used; True-FISP produces better edge sharpness than single-shot echo-train, higher contrast, and resists flow void artifacts commonly seen with single-shot echo-train imaging combined with a water distending agent.
  • Drawbacks of this technique include: artifacts related to extreme sensitivity to field inhomogeneity, including air-soft tissue interfaces at the patient skin surface, and from retained bowel gas; retained bowel gas is dark against dark bowel wall, impairing bowel wall assessment; and True-FISP does not provide sensitivity for edema, which is superior on single-shot echo-train imaging.
  • Small/large bowel indications for MRI include: inflammatory bowel disease, infectious disease including abscess evaluation or for appendicitis, inflammatory conditions including ischemia, and partial obstruction, malnutrition, and neoplasm search.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314698.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 71
  •  go-up   go-down


23. D'Adamo D: Advances in the treatment of gastrointestinal stromal tumor. Adv Ther; 2009 Sep;26(9):826-37
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of gastrointestinal stromal tumor.
  • GIST (gastrointestinal stromal tumor) is a rare soft tissue malignancy arising in the gut.
  • From a disease that 10 years ago was only treatable with surgery, now multiple phase 2 and phase 3 trials have identified active first-line systemic therapy, appropriate dosing, an active second-line agent, and established the role of adjuvant therapy after surgery for patients with intermediate- and high-risk tumors.
  • GIST has been the ideal disease system for studying targeted therapy in solid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-kit / antagonists & inhibitors
  • [MeSH-minor] Benzamides. Combined Modality Therapy. Drug Delivery Systems. Drug Resistance, Neoplasm. Drugs, Investigational. Humans. Imatinib Mesylate. Indoles / adverse effects. Indoles / therapeutic use. Piperazines / adverse effects. Piperazines / therapeutic use. Pyrimidines / adverse effects. Pyrimidines / therapeutic use. Pyrroles / adverse effects. Pyrroles / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19802531.001).
  • [ISSN] 1865-8652
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Drugs, Investigational; 0 / Indoles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 0 / sunitinib; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 36
  •  go-up   go-down


24. Bień E, Godziński J, Balcerska A, Rapała M, Izycka-Swieszewska E, Stachowicz-Stencel T, Sulka W, Kazanowska B, Reich A, Chybicka A, Madziara W, Bohosiewicz J, Perek-Polnik M, Perek D, Mańkowski P, Jankowski A, Nurzyńska-Flak J, Kowalczyk J, Kurylak A, Wysocki M, Rybczyńska A, Wachowiak J, Zalewska-Szewczyk B, Bodalski J, Jaśkiewicz K: [Malignant vascular tumours in children -- report from the Polish Pediatric Rare Tumors Study]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):145-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant vascular tumours represent a rare group of neoplasms, usually treated according to protocols for soft tissue sarcomas.
  • On the basis of the histological type of the neoplasm these patients have been divided into three groups: group I -- 10 patients with angiosarcoma (ASA), group II -- 7 children with haemangioendothelioma (HE) and group III- 15 patients with haemangiopericytoma (HP), of both infantile (7 children) and adult-types (8 patients).
  • Radiotherapy (RTX) was administered in 5 patients, chemotherapy (CHT) in all.
  • Adult-type HP: PRC was performed in 5 patients, resulting in local control in 4.
  • The high rate of metastatic relapses suggests that the currently given systemic therapy is not satisfactory.
  • The only tumour with excellent prognosis was infantile type HP (all patients are alive and free of disease).
  • Adequate treatment for children with angiosarcoma remains still unknown -- 9 of 10 patients died of disease progression.
  • Prognosis in patients with haemangioendothelioma is intermediate, however the role of immunotherapy should be further investigated.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Female. Humans. Male. Poland. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738588.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


25. Nascimento AF, Raut CP, Fletcher CD: Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol; 2008 Dec;32(12):1896-904
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary angiosarcoma is a rare neoplasm, accounting for about 0.05% of all primary malignancies of the breast.
  • Two patients had a history of prior radiation treatment for breast carcinoma.
  • Histologically, primary tumors were graded using Rosen's 3-tier system: 17 tumors (35.4%) as low grade, 17 (35.4%) as intermediate grade, and 14 (29.2%) as high grade.
  • Forty-six patients were treated surgically, 11 underwent chemotherapy, and 12 patients received radiotherapy.
  • Twenty-four patients (58.5%) thus far have developed metastases, which were most commonly to lung, liver, skin, and bone.
  • Time interval between diagnosis and metastasis ranged from 2 to 144 months (median 34).
  • This tumor seems to have an overall similar clinical course as other types of angiosarcoma arising in skin or soft tissue; it carries a moderate risk of local recurrence, and a high risk of metastasis and death.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813119.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement